预约演示
更新于：2025-09-02
Risvutatug Rezetecan
更新于：2025-09-02
概要
基本信息
原研机构 |
在研机构 |
非在研机构- |
最高研发阶段临床3期 |
首次获批日期- |
最高研发阶段(中国)临床3期 |
特殊审评突破性疗法 (美国)、优先药物（PRIME） (欧盟)、突破性疗法 (中国) |
登录后查看时间轴
结构/序列
使用我们的ADC技术数据为新药研发加速。
登录
或
Sequence Code 452958931L
来源: *****
Sequence Code 1376928427H
来源: *****
关联
27
项与 Risvutatug Rezetecan 相关的临床试验NCT07099898
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), Compared With Topotecan in Participants With Relapsed Small Cell Lung Cancer (SCLC)
NCT07115446
A Phase Ib Study to Explore the Safety, Tolerability, and Pharmacokinetics of HS-20093 Combination With HRS-5041 in Patients With Advanced Prostate Cancer
NCT07063407
A Phase I Clinical Study Evaluating Safety, Tolerability, Pharmacokinetics and Efficacy of Intravenous HS-20093 Combinations in Patients With Extensive Stage Small Cell Lung Cancer
100 项与 Risvutatug Rezetecan 相关的临床结果
登录后查看更多信息
100 项与 Risvutatug Rezetecan 相关的转化医学
登录后查看更多信息
100 项与 Risvutatug Rezetecan 相关的专利（医药）
登录后查看更多信息
2
项与 Risvutatug Rezetecan 相关的文献（医药）2024-02-01Journal of immunotherapy and precision oncology
B7-H3 Inhibitors in Oncology Clinical Trials: A Review
Review
作者: Martin, Jared ; Falchook, Gerald S. ; Feustel, Kavanya
ABSTRACT:
B7-H3 is a transmembrane receptor highly prevalent on malignant cells and plays an important role in adaptive immunity that is not fully elucidated. Targeted B7-H3 inhibitors, including antibody-drug conjugates, radioimmunotherapy, and monoclonal antibodies, are a new class of antineoplastic agents showing promising preliminary clinical efficacy, observed with several of these agents against multiple tumor types. Particularly promising treatments are enoblituzumab for prostate cancer, 131I-omburtamab for central nervous system malignancies, and HS-20093 for small-cell lung cancer but further studies are warranted. There are clinical trials on the horizon that have not yet enrolled patients examining chimeric antigen receptor T-cell therapies, bi- and tri-specific killer engagers, and dual-affinity retargeting proteins. These data will be telling of the efficacy of B7-H3 inhibitors in both hematologic and solid malignancies. This study aimed to compile available results of B7-H3 inhibitors in oncology clinical trials.
2024-01-01Translational oncology
B7-H3/CD276 and small-cell lung cancer: What's new?
Article
作者: Rossi, Antonio ; Fabrizio, Federico Pio ; Muscarella, Lucia Anna
Immunotherapy revolutionized the treatment landscape of several cancers, including small-cell lung cancer (SCLC), with a huge number of practice-changing trials, and becoming a new frontier for their management. The addition of an anti-PD-L1, atezolizumab or durvalumab, to platinum/etoposide regimen became the standard of care for first-line therapy of extensive-stage (ES)-SCLC with the 12 months median survival exceeded for the first time. Nevertheless, most patients show primary or acquired resistance to anti-PD-L1 therefore new promising therapeutic immune-targets are under clinical investigation in several solid tumors. Among these, B7-H3, also known as CD276, is a member of the B7 family overexpressed in tumor tissues, including SCLC, while showing limited expression in normal tissues becoming an attractive and promising target for cancer immunotherapy. B7-H3 plays a dual role in the immune system during the T-cell activation, acting as a T-cell costimulatory/coinhibitory immunoregulatory protein, and promoting pro-tumorigenic functions such as tumor migration, invasion, metastases, resistance, and metabolism. Immunohistochemistry, flow cytometry, and immunofluorescence were the most used methods to assess B7-H3 expression levels and validate a possible relationship between B7-H3 staining patterns and clinicopathological features in lung cancer patients. To date, there are no clinically available therapeutics/drugs targeting B7-H3 in any solid tumors. The most promising preliminary clinical results have been reported by DS7300a and HS-20093, both are antibody-drug conjugates, that are under investigation in ongoing trials for the treatment of pretreated SCLC. This review will provide an overview of B7-H3 and corresponding inhibitors and the clinical development in the management of SCLC.
188
项与 Risvutatug Rezetecan 相关的新闻（医药）2025-08-24
·信狐药迅
申请上市临床申请临床1期
2025-08-19
·美通社
引进/卖出临床3期抗体药物偶联物上市批准财报
2025-08-19
引进/卖出财报临床3期
100 项与 Risvutatug Rezetecan 相关的药物交易
登录后查看更多信息
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 骨肉瘤 | 临床3期 | 中国 | 2025-04-18 | |
| 局限期小细胞肺癌 | 临床3期 | - | 2024-09-30 | |
| 复发性小细胞肺癌 | 临床3期 | 中国 | 2024-07-04 | |
| 直肠腺癌 | 临床2期 | 美国 | 2025-06-11 | |
| 直肠腺癌 | 临床2期 | 日本 | 2025-06-11 | |
| 直肠腺癌 | 临床2期 | 澳大利亚 | 2025-06-11 | |
| 直肠腺癌 | 临床2期 | 加拿大 | 2025-06-11 | |
| 直肠腺癌 | 临床2期 | 韩国 | 2025-06-11 | |
| 广泛期小细胞肺癌 | 临床2期 | 中国 | 2024-03-01 | |
| 食管腺癌 | 临床2期 | 中国 | 2024-02-06 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1/2期 | 508 | 醖鹹遞淵製醖廠廠鬱繭(築衊壓壓鹽窪積鑰襯製) = neutrophil count decreased, white blood cell count decreased, lymphocyte count decreased and anaemia 積艱構襯簾襯衊鏇夢糧 (餘夢醖廠網襯鏇壓繭範 ) 更多 | 积极 | 2025-04-29 | |||
临床1期 | 56 | HS-20093 8.0 mg/kg | 遞蓋鏇顧鬱餘鬱襯積觸(鏇遞鬱蓋觸積選窪網餘) = 餘範繭構鬱醖蓋醖築繭 獵鹽鏇憲製鏇夢繭淵願 (願獵鏇鏇窪鏇齋齋淵顧 ) 更多 | 积极 | 2024-09-08 | ||
HS-20093 10.0 mg/kg | 遞蓋鏇顧鬱餘鬱襯積觸(鏇遞鬱蓋觸積選窪網餘) = 獵簾醖衊遞夢衊襯廠繭 獵鹽鏇憲製鏇夢繭淵願 (願獵鏇鏇窪鏇齋齋淵顧 ) 更多 | ||||||
临床1期 | 56 | 鹹襯餘觸積網鬱網窪餘(積壓鹽廠衊築觸夢選網) = 獵壓憲糧鏇遞鑰憲淵鹹 醖壓憲鹽膚蓋構衊選範 (觸襯醖蓋築製艱蓋遞鑰 ) 更多 | 积极 | 2024-05-24 | |||
鹹襯餘觸積網鬱網窪餘(積壓鹽廠衊築觸夢選網) = 壓觸艱顧網築製衊鹽夢 醖壓憲鹽膚蓋構衊選範 (觸襯醖蓋築製艱蓋遞鑰 ) 更多 | |||||||
临床2期 | 复发性骨肉瘤 末线 | 34 | HS-20093 12 mg/kg | 選積獵簾衊築製憲襯淵(築蓋蓋夢顧鑰蓋遞餘製) = 製糧願獵夢選顧簾鹽繭 鹽築窪選淵網鏇糧窪廠 (膚夢襯構鑰積觸膚觸餘 ) 更多 | 积极 | 2024-05-24 | |
(8.0 mg/kg) | 壓膚鹹糧醖壓壓繭醖鹽(築襯獵衊蓋衊鏇醖觸餘) = 窪鹹網壓製鏇網夢艱築 夢窪選糧簾壓鹹遞衊積 (鏇鑰醖糧廠鏇選築構醖 ) | ||||||
临床1期 | 53 | 鬱餘積蓋夢醖獵繭繭簾(範壓蓋鏇鏇選製淵網鑰) = 鑰淵選壓齋鹹網繭範繭 壓獵築遞憲範醖繭顧衊 (衊膚襯鑰廠餘獵簾簾夢 ) 更多 | 积极 | 2023-05-31 | |||
(SCLC) | 齋簾艱鑰獵餘積淵選繭(顧齋顧醖窪獵網範鹽鬱) = 夢淵窪艱顧醖鹽網顧觸 艱顧網網餘糧醖構繭築 (構選齋構齋鬱蓋鏇廠願 ) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用